Vectorialis
Non-viral nanoparticle technology for nucleic acid delivery.
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
| Total Funding | 000k | ||
Related Content
Vectorialis is a life sciences company specializing in technologies for advanced therapies and recombinant protein production. Based in Milan, Italy, the company was co-founded by Dr. Nina Bono (Managing Director), Dr. Gabriele Candiani (R&D Lead and Product Specialist), and Dario Caleffi (Sr. Business Analyst). The founders identified a critical bottleneck in genetic medicine research: the need for a more efficient, reliable, and less toxic method for delivering nucleic acids into cells.
The company's core offering is the VibroFect technology, a patented platform designed to improve the process of transfection. This system consists of two main components: a bench-top device that uses precise oscillatory motion for rapid mixing, and proprietary transfection reagents. The technology works by harnessing mechanical stimulation to create non-viral, biocompatible nanoparticles that encapsulate nucleic acids like mRNA, siRNA, and DNA. This process is notably rapid, forming nanovectors in just 10 seconds, and is designed to minimize cytotoxicity, thereby preserving cell viability and allowing for repeated treatments.
Vectorialis serves researchers and scientists in the fields of genetic medicine and biotechnology, targeting applications for genetic disorders, infectious diseases, and cancer. The business model centers on selling the VibroFect device and its associated reagents to research institutions, pharmaceutical companies, and academic labs. The primary benefit for clients is a significant increase in transfection efficiency, enhanced consistency of results, and reduced costs associated with wasted materials and failed experiments. The technology is compatible with a wide range of eukaryotic cells, including those that are typically hard to transfect.
Keywords: nucleic acid delivery, transfection technology, non-viral vectors, gene therapy, cell therapy, nanoparticle formulation, recombinant protein, drug delivery, biotechnology, life sciences, advanced therapies, VibroFect, genetic medicine, cell viability, hard-to-transfect cells, mRNA delivery, siRNA delivery, DNA delivery, nanomedicine, research tools